XML 40 R29.htm IDEA: XBRL DOCUMENT

Equity (Tables)

6 Months Ended

Jun. 30, 2025

Equity [Abstract]

Schedule of Equity


			Three Months Ended June 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at April 1, 2024			3,577			$	1,788		$	44,598		$	56,697		$	(5,274)		1,044			$	(57,445)		$	60		$	40,424
Net income attributable to Merck & Co., Inc.			—			—			—			5,455			—			—			—			—			5,455
Other comprehensive loss, net of taxes			—			—			—			—			(87)			—			—			—			(87)
Cash dividends declared on common stock ($0.77 per share)			—			—			—			(1,965)			—			—			—			—			(1,965)
Treasury stock shares purchased			—			—			—			—			—			2			(251)			—			(251)
Share-based compensation plans and other			—			—			(236)			—			—			(5)			302			—			66
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			6			6

Balance at June 30, 2024			3,577			$	1,788		$	44,362		$	60,187		$	(5,361)		1,041			$	(57,394)		$	66		$	43,648
Balance at April 1, 2025			3,577			$	1,788		$	44,816		$	66,097		$	(4,965)		1,061			$	(59,401)		$	65		$	48,400
Net income attributable to Merck & Co., Inc.			—			—			—			4,427			—			—			—			—			4,427
Other comprehensive loss, net of taxes			—			—			—			—			(456)			—			—			—			(456)
Cash dividends declared on common stock ($0.81 per share)			—			—			—			(2,047)			—			—			—			—			(2,047)
Treasury stock shares purchased			—			—			—			—			—			17			(1,345)			—			(1,345)
Share-based compensation plans and other			—			—			(172)			—			—			(4)			251			1			80
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			1			1

Balance at June 30, 2025			3,577			$	1,788		$	44,644		$	68,477		$	(5,421)		1,074			$	(60,495)		$	67		$	49,060


			Six Months Ended June 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at January 1, 2024			3,577			$	1,788		$	44,509		$	53,895		$	(5,161)		1,045			$	(57,450)		$	54		$	37,635
Net income attributable to Merck & Co., Inc.			—			—			—			10,217			—			—			—			—			10,217
Other comprehensive loss, net of taxes			—			—			—			—			(200)			—			—			—			(200)
Cash dividends declared on common stock ($1.54 per share)			—			—			—			(3,925)			—			—			—			—			(3,925)
Treasury stock shares purchased			—			—			—			—			—			3			(373)			—			(373)
Share-based compensation plans and other			—			—			(147)			—			—			(7)			429			1			283
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			11			11

Balance at June 30, 2024			3,577			$	1,788		$	44,362		$	60,187		$	(5,361)		1,041			$	(57,394)		$	66		$	43,648
Balance at January 1, 2025			3,577			$	1,788		$	44,704		$	63,069		$	(4,945)		1,049			$	(58,303)		$	59		$	46,372
Net income attributable to Merck & Co., Inc.			—			—			—			9,506			—			—			—			—			9,506
Other comprehensive loss, net of taxes			—			—			—			—			(476)			—			—			—			(476)
Cash dividends declared on common stock ($1.62 per share)			—			—			—			(4,098)			—			—			—			—			(4,098)
Treasury stock shares purchased			—			—			—			—			—			29			(2,509)			—			(2,509)
Share-based compensation plans and other			—			—			(60)			—			—			(4)			317			—			257
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			8			8

Balance at June 30, 2025			3,577			$	1,788		$	44,644		$	68,477		$	(5,421)		1,074			$	(60,495)		$	67		$	49,060